Truvestments Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Truvestments Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-177	Closed	-$4.13K	–	1268
2026 Q1	$4.13K	Sell	177 -154	-47%	-$3.35K	﹤0.01%	908
2025 Q4	$6.95K	Hold	331	–	–	﹤0.01%	748
2025 Q3	$5.09K	Sell	331 -495	-60%	-$6.48K	﹤0.01%	818
2025 Q2	$7.74K	Hold	826	–	–	﹤0.01%	683
2025 Q1	$10.1K	Sell	826 -89	-10%	-$1.25K	﹤0.01%	655
2024 Q4	$12.1K	Buy	915 +398	+77%	+$6.81K	﹤0.01%	575
2024 Q3	$9.95K	Buy	+517	New	+$10.7K	﹤0.01%	584
2024 Q2	–	Sell	-218	Closed	-$5.19K	–	616
2024 Q1	$5.19K	Hold	218	–	–	﹤0.01%	551
2023 Q4	$4.71K	Hold	218	–	–	﹤0.01%	604
2023 Q3	$3.17K	Hold	218	–	–	﹤0.01%	556
2023 Q2	$4.56K	Hold	218	–	–	﹤0.01%	536
2023 Q1	$4.6K	Buy	+218	New	+$5.42K	﹤0.01%	521

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Truvestments Capital's SNDX Position: Q2 2026 in Review

Truvestments Capital sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 177 shares — an estimated $4.13K sold.

Truvestments Capital first reported a position in SNDX in Q1 2023 and held it in 12 quarters. The position peaked at $12.1K in Q4 2024. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Truvestments Capital reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Truvestments Capital sold 177 Syndax Pharmaceuticals shares in Q2 2026, an estimated $4.13K.
Truvestments Capital first reported a position in Syndax Pharmaceuticals in Q1 2023 and held it in 12 quarters.
Truvestments Capital's Syndax Pharmaceuticals position peaked at $12.1K in Q4 2024.
243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.